Dr Thomas C. Krivak reviews a case of a 59-year-old woman who has stage IV, high-grade serous epithelial ovarian cancer and discusses ASCO and NCCN guideline recommendations for germline/somatic tumor testing.
Practice Updates in Ovarian Cancer
Cecelia H. Boardman, MD, John K. Chan, MD, and Ashley Farione, PA-C, discuss their treatment approach to genetic testing in patients with advanced ovarian cancer.
John K. Chan, MD, leads a discussion on the role of first-line maintenance therapy for advanced ovarian cancer and the standard of care first-line maintenance approaches for a patient with gBRCA2-mutated disease.
A panel of experts share insight on patient factors to consider when selecting first-line maintenance therapy for advanced ovarian cancer.
Experts in gynecologic oncology review data and clinical implications for the use of PARP inhibitors from the GOG-0218, SOLO-1, PRIMA, and PAOLA-1 trials in advanced ovarian cancer.
Thomas C. Krivak, MD, leads a discussion on guideline recommendations regarding the use of PARP inhibitors in newly diagnosed advanced ovarian cancer.
Cecelia H. Boardman, MD, John K. Chan, MD, and Thomas C. Krivak, MD, provide insight on dosing schedules for niraparib maintenance in advanced ovarian cancer.
Experts in gynecologic oncology review the case of a 71-year-old woman who is diagnosed with stage III, high-grade serous epithelial ovarian cancer, and comment on their approach to genetic testing in the frontline setting.
Thomas C. Krivak, MD; John K. Chan, MD; Cecelia H. Boardman, MD; and Ashley Farione, PA-C, review the optimal approach to maintenance therapeutic options for a patient with stage III, high-grade serous epithelial ovarian cancer.
Cecelia H. Boardman, MD, John K. Chan, MD, and Thomas C. Krivak, MD, share strategies for monitoring adverse events and the optimal duration for niraparib maintenance therapy for a patient with advanced ovarian cancer.
Experts in gynecologic oncology review the case of a 69-year-old woman with newly diagnosed high-serous carcinoma and discuss their approach to maintenance therapy after first-line chemotherapy plus bevacizumab.
Thomas C. Krivak, MD, leads a discussion on initiating antihypertensive therapy for patients with ovarian cancer who develop treatment-associated hypertension.
Thomas C. Krivak MD, John K. Chan, MD, and Cecelia H. Boardman, MD, share insight on recent updates to maintenance therapy, unmet needs, and the future treatment landscape for ovarian cancer.